Porter Adventist Hospital

The trials here

What the 61 trials at this site are about, from their registry records.

Conditions

• Lung cancer9 trials
• Prostate cancer9 trials
• Colorectal cancer5 trials
• Childhood cancers4 trials
• Head and neck cancer4 trials
• Melanoma4 trials
• Metastatic breast cancer3 trials
• Multiple myeloma3 trials
• Chronic myeloid leukaemia2 trials
• Liver and biliary tract cancer2 trials
• Mantle cell lymphoma2 trials
• Ovarian cancer2 trials
• and 16 more

Phase

• Phase 227 trials
• Phase 325 trials
• Phase 2/34 trials

Status

• Active, not recruiting35 trials
• Completed20 trials
• Recruiting3 trials
• Suspended2 trials
• Terminated1 trial

Lead sponsor

• SWOG Cancer Research Network19 trials
• ECOG-ACRIN Cancer Research Group17 trials
• Alliance for Clinical Trials in Oncology10 trials
• Radiation Therapy Oncology Group4 trials
• National Cancer Institute (NCI)3 trials
• and 6 more

Running trials

• Recruiting

  Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

  NCT05806515· Phase 2· SWOG Cancer Research Network· Source

  Contact: Shahzad Siddique (principal investigator)

• Active, not recruiting

  Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

  NCT05694871· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

  NCT05241860· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

  NCT04637594· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

  NCT04455750· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

  NCT04597359· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

  NCT04647916· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

  NCT04559139· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

  NCT04462406· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

  NCT04533451· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

  NCT04233866· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

  NCT04137107· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

  NCT04248452· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

  NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

  NCT04115631· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

  NCT04071457· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

  NCT03516279· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

  NCT03654768· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

  NCT03678025· Phase 3· SWOG Cancer Research Network· Source

  Contact: Shahzad Siddique (principal investigator)

• Recruiting

  S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928· SWOG Cancer Research Network· Source

  Contact: Shahzad Siddique (principal investigator)

• Active, not recruiting

  Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

  NCT03516942· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

  NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771· Phase 2· NRG Oncology· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

  NCT02595424· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

  NCT01898494· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT01415752· Phase 2· Eastern Cooperative Oncology Group· Source

• Active, not recruiting

  Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source

• Active, not recruiting

  Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

  NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source

• Active, not recruiting

  RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source

• Active, not recruiting

  Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

  NCT00499330· Alliance for Clinical Trials in Oncology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Terminated

  Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

  NCT03963739· Wake Forest University Health Sciences· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186· Phase 2· Wake Forest University Health Sciences· Source

• Completed

  Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

  NCT03602586· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916· Children's Oncology Group· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691· Phase 3· SWOG Cancer Research Network· Source

• Completed

  S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

  NCT01359592· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

  NCT01302834· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451· Phase 3· GOG Foundation· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source